![Brian Silver](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brian Silver
Direttore/Membro del Consiglio presso Novalgen Ltd.
Patrimonio netto: 281 167 $ in data 31/05/2024
Profilo
Brian Michael Silver is a Non-Executive Director at Novalgen Ltd.
He previously worked as an MD-HealthCare Investment Banking Group at Morgan Stanley from 1998 to 2013.
Before that, he was an Associate at Sullivan & Cromwell LLP from 1994 to 1997.
Brian also served as the Chief Financial Officer & Treasurer at TScan Therapeutics, Inc. from 2021 to 2023, and as the CFO & Head-Corporate Development at Freeline Therapeutics Holdings Plc from 2018 to 2021.
Prior to that, he was the Head-Biotechnology & Partner at Perella Weinberg Partners from 2013 to 2018.
Mr. Silver holds a graduate degree from The University of Chicago Law School and an undergraduate degree from Harvard College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0.07% | 31/03/2024 | 32 885 ( 0.07% ) | 281 167 $ | 31/05/2024 |
Posizioni attive di Brian Silver
Società | Posizione | Inizio |
---|---|---|
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Brian Silver
Società | Posizione | Fine |
---|---|---|
TSCAN THERAPEUTICS, INC. | Direttore Finanziario/CFO | 21/07/2023 |
FREELINE THERAPEUTICS HOLDINGS PLC | Direttore Finanziario/CFO | 30/04/2021 |
PERELLA WEINBERG PARTNERS | Corporate Officer/Principal | 01/11/2018 |
MORGAN STANLEY | Corporate Officer/Principal | 01/07/2013 |
Sullivan & Cromwell LLP
![]() Sullivan & Cromwell LLP Miscellaneous Commercial ServicesCommercial Services Sullivan & Cromwell LLP provides legal services. It specializes in the areas of corporate law, securities, corporate, litigation, mergers, real estate, pro bono, investment management and taxation. Their clients include industrial, commercial, financial, private funds, governmental, educational, charitable and cultural enterprises and entities. The company was founded by Algernon Sydney Sullivan and William Nelson Cromwell in 1879 and is headquartered in New York City, NY. | Corporate Officer/Principal | 01/01/1997 |
Formazione di Brian Silver
The University of Chicago Law School | Graduate Degree |
Harvard College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
TSCAN THERAPEUTICS, INC. | Health Technology |
PERELLA WEINBERG PARTNERS | Finance |
MORGAN STANLEY | Finance |
Aziende private | 3 |
---|---|
Freeline Therapeutics Holdings Plc
![]() Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Sullivan & Cromwell LLP
![]() Sullivan & Cromwell LLP Miscellaneous Commercial ServicesCommercial Services Sullivan & Cromwell LLP provides legal services. It specializes in the areas of corporate law, securities, corporate, litigation, mergers, real estate, pro bono, investment management and taxation. Their clients include industrial, commercial, financial, private funds, governmental, educational, charitable and cultural enterprises and entities. The company was founded by Algernon Sydney Sullivan and William Nelson Cromwell in 1879 and is headquartered in New York City, NY. | Commercial Services |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Brian Silver